Fig. 6
FAK inhibitor enhanced anti-tumor effect and mediated positive TME in KL tumors. A Volume change in mean (main) and individual (insert, “spider plots”) subcutaneous implanted tumors following treatment of FAK inhibitor (25 mg/kg) or control (0.5% Natrosol 250 HX) beginning at the day when implanted tumor volume reached 100-150mm3. Two-way analysis of variance (ANOVA) was performed. B Representative flow cytometry images at Day 7 and histogram showed the percentage of intratumoral CD3+ of CD45+ cells at different time points. Ratio of intratumoral C CD19+ cells, D CD3−NK1.1+ cells to CD45+cells at indicated time points. E Representative flow cytometry images at Day 14 and histogram showed the percentage of intratumoral CD8+ of CD45+ cells at indicated time points. F Ratio of CD4+Foxp3+ to CD3+ cells at indicated time points. G Representative flow cytometry images at Day 14 and histogram showed the percentage of intratumoral M-MDSC and PMN-MDSC at indicated time points. H Representative flow cytometry images at Day 14 and histogram showed the percentage of intratumoral CD11c+MHCII+of CD45+ cells at indicated time points. I Ratio of CD11b+F4/80+ cells and further quantification of macrophage subtypes (M1-like: CD86+, M2-like: CD206+) in two groups at indicated time points. Unpaired Student’s t-test was performed and results in each group were presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and nsp-values with no statistical difference. KL, KRASG12DLKB1−/−; TME, tumor microenvironment; FAK, focal adhesion kinase; NK, nature killer; MHC, major histocompatibility complex; Foxp3, forkhead box P3; M-MDSC, monocytic-myeloid-derived suppressor cells; PMN-MDSC, polymorphonucler-myeloid derived suppressor cells; SEM, standard error of mean